Giulia C. Kennedy's most recent trade in Veracyte Inc was a trade of 1,023 Common Stock done at an average price of $27.0 . Disclosure was reported to the exchange on Dec. 6, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 27.03 per share. | 06 Dec 2022 | 1,023 | 65,970 (0%) | 0% | 27.0 | 27,652 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.14 per share. | 02 Dec 2022 | 1,008 | 66,993 (0%) | 0% | 29.1 | 29,373 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.50 per share. | 11 Nov 2022 | 2 | 68,003 (0%) | 0% | 14.5 | 29 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2022 | 2 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 29.50 per share. | 11 Nov 2022 | 2 | 68,001 (0%) | 0% | 29.5 | 59 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2022 | 1,023 | 68,001 (0%) | 0% | 25 | 25,575 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 02 Sep 2022 | 1,008 | 69,024 (0%) | 0% | 19.2 | 19,333 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 18,248 | 18,248 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 10,702 | 71,055 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 26.54 per share. | 05 Aug 2022 | 1,028 | 70,032 (0%) | 0% | 26.5 | 27,283 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.50 per share. | 05 Aug 2022 | 2 | 71,057 (0%) | 0% | 10.5 | 21 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.50 per share. | 05 Aug 2022 | 2 | 71,059 (0%) | 0% | 6.5 | 13 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 2 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 2 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 1 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 05 Aug 2022 | 1 | 71,060 (0%) | 0% | 5 | 5 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.23 per share. | 02 Jun 2022 | 1,008 | 60,353 (0%) | 0% | 18.2 | 18,376 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 77,287 | 77,287 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 42,412 | 79,987 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 24.91 per share. | 03 Mar 2022 | 17,089 | 67,305 (0%) | 0% | 24.9 | 425,697 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 25.70 per share. | 03 Mar 2022 | 5,844 | 61,461 (0%) | 0% | 25.7 | 150,189 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2022 | 4,407 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 03 Mar 2022 | 4,407 | 84,394 (0%) | 0% | 6.0 | 26,354 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 26.49 per share. | 03 Mar 2022 | 100 | 61,361 (0%) | 0% | 26.5 | 2,649 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.84 per share. | 02 Mar 2022 | 10,337 | 37,575 (0%) | 0% | 27.8 | 287,782 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 06 Dec 2021 | 4,406 | 53,394 (0%) | 0% | 6.0 | 26,348 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 4,406 | 4,407 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 39.69 per share. | 06 Dec 2021 | 4,375 | 49,662 (0%) | 0% | 39.7 | 173,644 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 06 Dec 2021 | 4,375 | 52,287 (0%) | 0% | 24.7 | 108,019 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 4,375 | 39,375 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 36.11 per share. | 06 Dec 2021 | 3,897 | 49,697 (0%) | 0% | 36.1 | 140,709 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 06 Dec 2021 | 3,750 | 57,144 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 3,750 | 18,750 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 35.37 per share. | 06 Dec 2021 | 3,550 | 53,594 (0%) | 0% | 35.4 | 125,565 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 37.26 per share. | 06 Dec 2021 | 1,785 | 47,912 (0%) | 0% | 37.3 | 66,510 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.55 per share. | 06 Dec 2021 | 1,750 | 54,037 (0%) | 0% | 26.6 | 46,463 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 1,750 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 41.55 per share. | 06 Dec 2021 | 1,750 | 47,912 (0%) | 0% | 41.6 | 72,713 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.22 per share. | 02 Dec 2021 | 912 | 48,988 (0%) | 0% | 39.2 | 35,769 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.80 per share. | 01 Nov 2021 | 149 | 49,900 (0%) | 0% | 51.8 | 7,718 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 50.52 per share. | 07 Sep 2021 | 12,034 | 51,472 (0%) | 0% | 50.5 | 607,946 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 4,406 | 8,813 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 07 Sep 2021 | 4,406 | 55,381 (0%) | 0% | 6.0 | 26,348 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 07 Sep 2021 | 4,375 | 63,506 (0%) | 0% | 24.7 | 108,019 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 4,375 | 43,750 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 3,750 | 22,500 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 07 Sep 2021 | 3,750 | 59,131 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 50.53 per share. | 07 Sep 2021 | 926 | 50,049 (0%) | 0% | 50.5 | 46,791 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 51.23 per share. | 07 Sep 2021 | 497 | 50,975 (0%) | 0% | 51.2 | 25,463 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.97 per share. | 02 Sep 2021 | 912 | 50,975 (0%) | 0% | 53.0 | 48,309 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 39.75 per share. | 23 Jun 2021 | 4,375 | 51,887 (0%) | 0% | 39.8 | 173,914 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2021 | 4,375 | 48,125 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 23 Jun 2021 | 4,375 | 56,262 (0%) | 0% | 24.7 | 108,019 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 35.17 per share. | 04 Jun 2021 | 4,979 | 51,887 (0%) | 0% | 35.2 | 175,112 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 04 Jun 2021 | 4,406 | 57,218 (0%) | 0% | 6.0 | 26,348 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2021 | 4,406 | 13,219 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2021 | 3,750 | 26,250 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 04 Jun 2021 | 3,750 | 60,968 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 34.39 per share. | 04 Jun 2021 | 2,595 | 56,866 (0%) | 0% | 34.4 | 89,251 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 33.28 per share. | 04 Jun 2021 | 1,507 | 59,461 (0%) | 0% | 33.3 | 50,151 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.07 per share. | 02 Jun 2021 | 912 | 52,812 (0%) | 0% | 36.1 | 32,896 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 47.11 per share. | 04 Mar 2021 | 20,239 | 85,500 (0%) | 0% | 47.1 | 953,544 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 04 Mar 2021 | 17,500 | 105,739 (0%) | 0% | 24.7 | 432,075 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 17,500 | 52,500 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 48.29 per share. | 04 Mar 2021 | 8,483 | 77,017 (0%) | 0% | 48.3 | 409,608 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 51.38 per share. | 04 Mar 2021 | 8,114 | 63,093 (0%) | 0% | 51.4 | 416,901 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 04 Mar 2021 | 5,313 | 80,082 (0%) | 0% | 9.1 | 48,083 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 5,313 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 52.38 per share. | 04 Mar 2021 | 5,032 | 58,061 (0%) | 0% | 52.4 | 263,564 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 04 Mar 2021 | 4,407 | 84,489 (0%) | 0% | 6.0 | 26,354 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 4,407 | 17,625 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 04 Mar 2021 | 3,750 | 88,239 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 3,750 | 30,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 49.22 per share. | 04 Mar 2021 | 2,991 | 74,026 (0%) | 0% | 49.2 | 147,210 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 50.40 per share. | 04 Mar 2021 | 2,819 | 71,207 (0%) | 0% | 50.4 | 142,073 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 53.50 per share. | 04 Mar 2021 | 2,606 | 55,455 (0%) | 0% | 53.5 | 139,414 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 54.72 per share. | 04 Mar 2021 | 1,431 | 54,024 (0%) | 0% | 54.7 | 78,310 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 55.49 per share. | 04 Mar 2021 | 300 | 53,724 (0%) | 0% | 55.5 | 16,647 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.15 per share. | 02 Mar 2021 | 5,995 | 74,769 (0%) | 0% | 62.1 | 372,589 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 12,500 | 80,764 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.30 per share. | 24 Feb 2021 | 10,048 | 68,264 (0%) | 0% | 62.3 | 625,990 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 57.55 per share. | 02 Dec 2020 | 6,094 | 78,312 (0%) | 0% | 57.6 | 350,732 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2020 | 5,312 | 5,313 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 02 Dec 2020 | 5,312 | 84,171 (0%) | 0% | 9.1 | 48,074 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2020 | 4,406 | 22,032 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 02 Dec 2020 | 4,406 | 88,577 (0%) | 0% | 6.0 | 26,348 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 56.86 per share. | 02 Dec 2020 | 4,279 | 84,406 (0%) | 0% | 56.9 | 243,285 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2020 | 3,750 | 33,750 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 02 Dec 2020 | 3,750 | 92,327 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 55.78 per share. | 02 Dec 2020 | 3,642 | 88,685 (0%) | 0% | 55.8 | 203,140 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.08 per share. | 02 Dec 2020 | 540 | 78,859 (0%) | 0% | 55.1 | 29,743 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 06 Oct 2020 | 2,500 | 81,899 (0%) | 0% | 20.2 | 50,525 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2020 | 2,500 | 37,500 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 35.21 per share. | 06 Oct 2020 | 2,500 | 79,399 (0%) | 0% | 35.2 | 88,025 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 04 Sep 2020 | 3,542 | 83,489 (0%) | 0% | 9.0 | 32,055 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 3,542 | 10,625 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 2,937 | 26,438 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 04 Sep 2020 | 2,937 | 86,426 (0%) | 0% | 6.0 | 17,563 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 04 Sep 2020 | 2,536 | 83,890 (0%) | 0% | 30.1 | 76,208 | Common Stock |
| Veracyte Inc | Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 31.21 per share. | 04 Sep 2020 | 2,350 | 81,540 (0%) | 0% | 31.2 | 73,339 | Common Stock |